Biotech Values

[apljack]

EYEN: This has traded in a range for the past couple of months. They are in process of submitting the NDA for in-clinic Mydriasis, which should be any easy win. The company is still strictly clinical development with no sales force or stated roll-out plans, by CEO, Dr. Sean Ianchulev, was a lead developer for Lucentis, is on faculty at UCSF. I'm confident that this company will move past a pure development stage to commercialization and it is likely (IMO) that the company has well-developed plans for this that they are keeping close to the vest until the NDA is accepted. I doubt that there will be a true breakout until that is announced.